Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
We aim to (1) define trends in pediatric gabapentinoid prescribing (label and off-label) over 7 years, and (2) evaluate use in chronic pain clinic (CPC) patients during 2018. Retrospective data from a tertiary-care pediatric hospital were collected between 2013 and 2019. González-Bueno J, Calvo-Cidoncha E, Desongles-Corrales T, et al. DI-024 off-label use of gabapentin and pregabalin in a tertiary hospital. Eur J Hosp Pharm 2015; 22: A84–A85. Crossref In the same year, pregabalin, a structural analogue of gabapentin, was licenced for the treatment of neuropathic pain and as an adjunct in the management of epilepsy. 5–7 Pregabalin has since been licenced to treat generalised anxiety disorder. 8 Gabapentin has a long history of off-label prescription. 9 Between 1998 and 2000, a study The overall off-label use was 43% (28 patients), with no differences between the drugs (44% gabapentin and 43% pregabalin). The off-label use was related to the therapeutic indication (25 The off-label use of gabapentinoids is a significant yet understudied issue, particularly in Nepal. This study aimed to address the research gaps by analyzing the prescribing patterns of gabapentin and pregabalin at a tertiary care hospital in Nepal. Gabapentinoid prescriptions are increasing in North America, with frequent off-label use despite limited proven efficacy. This retrospective cohort study describes prescribing trends among hospitalized patients with a focus on dosing and deprescribing. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag . Desongles-Corrales T, et al. DI-024 . Off-label use of gabapentin and pregabalin in a tertiary hospital. Eur J Hosp . For gabapentin, the only pain-related indication approved by the US Food and Drug Administration (FDA) is postherpetic neuralgia. For pregabalin, FDA-approved indications related to pain are limited to postherpetic neuralgia, neuropathic pain associated with diabetic neuropathy or spinal cord injury, and fibromyalgia. Off-label use is the use of pharmaceutical drugs for an indication, age group, dosage, or route of administration that is not approved by the regulatory agencies and is not mentioned in the prescribing information for the drug. Off-label use is not illegal unless it violates safety regulation and ethical guidelines. The overall off-label use was 43% (28 patients), with no differences between the drugs (44% gabapentin and 43% pregabalin). The off-label use was related to the therapeutic indication (25 González-Bueno J, Calvo-Cidoncha E, Desongles-Corrales T, et al. DI-024 off-label use of gabapentin and pregabalin in a tertiary hospital. Eur J Hosp Pharm 2015; 22: A84–A85. Crossref We aim to (1) define trends in pediatric gabapentinoid prescribing (label and off-label) over 7 years, and (2) evaluate use in chronic pain clinic (CPC) patients during 2018. Methods: Retrospective data from a tertiary-care pediatric hospital were collected between 2013 and 2019. Despite having failed to demonstrate clinically relevant differences over gabapentin, pregabalin holds a high prescription rate with consequent extra costs for the hospital, representing an area in which rational drug use could be promoted. Background Gabapentin and pregabalin are two GABA analogues, example of an evergreening strategy. Both have been associated with a markedly off-label use Gabapentin and pregabalin for pain — is increased prescribing a cause for concern? Copyright © 2025 by Society of Hospital Medicine or related companies. All rights reserved. ISSN 1553-5606. Click on the article title to read more. Off-label use was prevalent, with 96.1% of prescriptions being off-label by FDA indications and 28.1% by BNF indications. Pregabalin was prescribed at a sub-therapeutic dose (75 mg/day) for neuropathic pain. Gabapentinoids (gabapentin and pregabalin) are widely used as analgesics but are labeled in pediatrics only for epilepsy. We aim to (1) define trends in pediatric gabapentinoid prescribing (label and off-label) over 7 years, and (2) evaluate use in chronic pain clinic (CPC) patients during 2018. Supporting: 1, Mentioning: 6 - BackgroundGabapentin and pregabalin are two GABA analogues, example of an evergreening strategy. Both have been associated with a markedly off-label use.PurposeTo describe the extent and nature of the off-label use of gabapentin and pregabalin.Material and methodsProspective observational study performed in a tertiary hospital. We included patients being treated The off-label use of gabapentinoids is believed to constitute a significant portion of all prescriptions, although determining accurate prevalence rates at both the national and global levels can be difficult. 8 Gabapentinoids are frequently prescribed for different therapeutic indications, including chronic back pain, perioperative pain Explore millions of resources from scholarly journals, books, newspapers, videos and more, on the ProQuest Platform. The overall off-label use was 43% (28 patients), with no differences between the drugs (44% gabapentin and 43% pregabalin). The off-label use was related to the therapeutic indication (25 patients) or the dose (3 patients).
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |